ATE517920T1 - Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) - Google Patents

Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)

Info

Publication number: ATE517920T1
Authority: AT; Austria
Prior art keywords: ifnar; humanized antibodies; antibodies against; interferon alpha; alpha receptor
Prior art date: 2003-04-23

Application number

AT04750579T

Other languages

English (en)

Inventor

Josephine Cardarelli

Tseng-Hui Chen

David King

Christopher Bebbington

Sarah Pogue

Francis J Carr

Stephen Williams

Original Assignee

Medarex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-23

Filing date

2004-04-23

Publication date

2011-08-15

2004-04-23 Application filed by Medarex Inc filed Critical Medarex Inc

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE517920T1 publication Critical patent/ATE517920T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Transplantation (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Neurology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04750579T 2003-04-23 2004-04-23 Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) ATE517920T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46505803P	2003-04-23	2003-04-23
PCT/US2004/012649 WO2004094473A2 (en)	2003-04-23	2004-04-23	Humanized antibodies to interferon alpha receptor-1 (ifnar-1)

Publications (1)

Publication Number	Publication Date
ATE517920T1 true ATE517920T1 (de)	2011-08-15

Family

ID=33310989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04750579T ATE517920T1 (de)	2003-04-23	2004-04-23	Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)

Country Status (14)

Country	Link
US (3)	US7619070B2 (de)
EP (2)	EP2404615A1 (de)
JP (3)	JP2007525458A (de)
KR (2)	KR20080045765A (de)
CN (1)	CN1795010A (de)
AT (1)	ATE517920T1 (de)
AU (1)	AU2004233346B2 (de)
BR (1)	BRPI0410492A (de)
CA (1)	CA2523142A1 (de)
ES (1)	ES2368737T3 (de)
MX (1)	MXPA05011406A (de)
NZ (1)	NZ542988A (de)
WO (1)	WO2004094473A2 (de)
ZA (1)	ZA200508389B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4394350B2 (ja)	2001-01-09	2010-01-06	ベイラーリサーチインスティテュート	対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ
NZ542988A (en) *	2003-04-23	2008-07-31	Medarex Inc	Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
CA2522957C (en) *	2003-04-23	2013-10-22	Medarex, Inc.	Compositions and methods for the therapy of inflammatory bowel disease
ES2643237T3 (es)	2004-06-21	2017-11-21	E. R. Squibb & Sons, L.L.C.	Anticuerpos del receptor 1 de interferón alfa y sus usos
AU2011236019B2 (en) *	2004-06-21	2012-12-13	E. R. Squibb & Sons, L.L.C.	Interferon alpha receptor 1 antibodies and their uses
EP1773391A4 (de) *	2004-06-25	2009-01-21	Medimmune Inc	Erhöhung der produktion rekombinater antikörper in säugetierzellen durch zielgerichtete mutagenese
US7888481B2 (en)	2005-02-10	2011-02-15	Baylor Research Institute	Anti-interferon alpha monoclonal antibodies and methods for use
EP1851248B1 (de)	2005-02-10	2016-08-10	Baylor Research Institute	Monoklonale anti-interferon-alpha-antikörper und verwendungsverfahren dafür
DK2594591T3 (en) *	2005-08-11	2018-07-30	Matossian Rogers Arpi	TCR-V-BETA RELATED PEPTIDES FOR TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASE
CN101473045B (zh) *	2006-04-24	2016-08-03	健泰科生物技术公司	用于检测自身免疫性病症的方法和组合物
JP2007306828A (ja) *	2006-05-17	2007-11-29	Tokai Univ	非還元マンノース残基を認識するファージ提示型単鎖抗体
US20090010966A1 (en) *	2007-06-21	2009-01-08	Angelica Therapeutics, Inc.	Modified diphtheria toxins
EP2268297A4 (de) *	2008-02-29	2011-11-16	Angelica Therapeutics Inc	Modifizierte toxine
EP2328615A2 (de) *	2008-08-20	2011-06-08	Centocor Ortho Biotech Inc.	Manipulierte anti-il-13-antikörper, zusammensetzungen, verfahren und verwendungen
GB0817891D0 (en)	2008-09-30	2008-11-05	Medical Res Council	Antibodies against il-25
SMT201700063T1 (it)	2009-09-03	2017-03-08	Medimmune Llc	Diagnosi di interferoni di tipo 1
JP5310878B2 (ja)	2011-02-17	2013-10-09	株式会社ニコン	投射型表示装置、携帯型電子機器およびデジタルカメラ
US8989867B2 (en)	2011-07-14	2015-03-24	Cyberonics, Inc.	Implantable nerve wrap for nerve stimulation configured for far field radiative powering
EP2968450A4 (de)	2013-03-15	2016-10-26	Angelica Therapeutics Inc	Modifizierte toxine
TWI713453B (zh) *	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
CN107074943B (zh) *	2016-07-14	2018-08-24	中国科学院生物物理研究所	I型干扰素受体抗体及其用途
SG11202101946YA (en) *	2018-09-18	2021-04-29	I Mab Biopharma Hangzhou Co Ltd	Anti-ifnar1 antibodies for treating autoimmune diseases
JP7386877B2 (ja)	2019-01-31	2023-11-27	イミューンセントバイオテクノロジー，インコーポレイテッド	新規の抗ｉｆｎａｒ１抗体
EP3924383A1 (de)	2019-02-15	2021-12-22	Astrazeneca AB	Interferon-vermittelte störungen vom typ i
WO2021203013A2 (en)	2020-04-03	2021-10-07	Viela Bio, Inc.	Methods of treating immune mediated pulmonary injury
CN113521276B (zh) *	2021-07-13	2022-04-12	江苏荃信生物医药股份有限公司	包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US5156840A (en)	1982-03-09	1992-10-20	Cytogen Corporation	Amine-containing porphyrin derivatives
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US5374548A (en)	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es)	1985-06-26	1992-08-01	Liposome Co Inc	Metodo para acoplamiento de liposomas.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5057313A (en)	1986-02-25	1991-10-15	The Center For Molecular Medicine And Immunology	Diagnostic and therapeutic antibody conjugates
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
IL78444A (en) *	1986-04-08	1992-05-25	Yeda Res & Dev	Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US5889151A (en)	1989-10-20	1999-03-30	Societe Leb-Tech	Purified human alpha interferon receptor
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
EP0563487A1 (de) *	1992-03-31	1993-10-06	Laboratoire Europeen De Biotechnologie S.A.	Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
GB9223377D0 (en)	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
AU7782894A (en) *	1993-09-17	1995-04-03	Laboratoire Europeen De Biotechnologie S.A.	Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US5818453A (en) *	1996-01-05	1998-10-06	Weavexx Corporation	System for evaluating print quality for a sheet
BR9708910A (pt) *	1996-05-04	1999-08-03	Zeneca Ltd	Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
AU731817C (en) *	1996-11-27	2001-11-01	Genentech Inc.	Humanized anti-CD11a antibodies
EP0983303B1 (de) *	1997-05-21	2006-03-08	Biovation Limited	Verfahren zur herstellung von nicht-immunogenen proteinen
WO2000058362A1 (en) *	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
AR024464A1 (es) *	1999-06-25	2002-10-02	Genentech Inc	Anticuerpos anti-erbb2 humanizados.
HU227039B1 (en)	2000-01-25	2010-05-28	Egis Gyogyszergyar Nyilvanosan	New process for the production of quetiapine and intermediates therefor
GB0001712D0 (en)	2000-01-25	2000-03-15	Pharma Pacific Pty Ltd	Therapeutic peptides
GB0001710D0 (en) *	2000-01-25	2000-03-15	Pharma Pacific Pty Ltd	Therapeutic treatment
JP2005512962A (ja) *	2001-09-20	2005-05-12	アレクシオンファーマシューティカルズ，インコーポレイテッド	抗ｐｄｇｆ抗体および設計抗体の産生方法
NZ542988A (en) *	2003-04-23	2008-07-31	Medarex Inc	Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
CA2522957C (en) *	2003-04-23	2013-10-22	Medarex, Inc.	Compositions and methods for the therapy of inflammatory bowel disease
US8162912B2 (en)	2008-05-30	2012-04-24	Kimberly Clark Worldwide, Inc.	Personal wear absorbent article with disposal tab

2004
- 2004-04-23 NZ NZ542988A patent/NZ542988A/en unknown
- 2004-04-23 CN CNA2004800141023A patent/CN1795010A/zh active Pending
- 2004-04-23 BR BRPI0410492-7A patent/BRPI0410492A/pt not_active IP Right Cessation
- 2004-04-23 EP EP10011473A patent/EP2404615A1/de not_active Withdrawn
- 2004-04-23 JP JP2006513277A patent/JP2007525458A/ja active Pending
- 2004-04-23 KR KR1020087010204A patent/KR20080045765A/ko not_active Ceased
- 2004-04-23 CA CA002523142A patent/CA2523142A1/en not_active Abandoned
- 2004-04-23 AU AU2004233346A patent/AU2004233346B2/en not_active Ceased
- 2004-04-23 MX MXPA05011406A patent/MXPA05011406A/es unknown
- 2004-04-23 KR KR1020057020179A patent/KR100872210B1/ko not_active Expired - Fee Related
- 2004-04-23 AT AT04750579T patent/ATE517920T1/de not_active IP Right Cessation
- 2004-04-23 WO PCT/US2004/012649 patent/WO2004094473A2/en not_active Ceased
- 2004-04-23 ES ES04750579T patent/ES2368737T3/es not_active Expired - Lifetime
- 2004-04-23 EP EP04750579A patent/EP1631590B1/de not_active Expired - Lifetime
- 2004-04-23 US US10/831,459 patent/US7619070B2/en not_active Expired - Fee Related
2005
- 2005-10-17 ZA ZA200508389A patent/ZA200508389B/xx unknown
2009
- 2009-09-28 JP JP2009223533A patent/JP2009298818A/ja active Pending
- 2009-09-29 US US12/569,205 patent/US7888484B2/en not_active Expired - Fee Related
2010
- 2010-11-18 JP JP2010258382A patent/JP2011032292A/ja active Pending
- 2010-12-20 US US12/972,813 patent/US8758757B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2004094473A3 (en)	2005-06-02
JP2007525458A (ja)	2007-09-06
US20050208041A1 (en)	2005-09-22
NZ542988A (en)	2008-07-31
US7888484B2 (en)	2011-02-15
US7619070B2 (en)	2009-11-17
ZA200508389B (en)	2006-10-25
WO2004094473A2 (en)	2004-11-04
ES2368737T3 (es)	2011-11-21
BRPI0410492A (pt)	2006-06-13
CA2523142A1 (en)	2004-11-04
US20100104569A1 (en)	2010-04-29
CN1795010A (zh)	2006-06-28
KR20060011968A (ko)	2006-02-06
AU2004233346A1 (en)	2004-11-04
EP1631590B1 (de)	2011-07-27
KR100872210B1 (ko)	2008-12-05
EP1631590A2 (de)	2006-03-08
US8758757B2 (en)	2014-06-24
KR20080045765A (ko)	2008-05-23
EP2404615A1 (de)	2012-01-11
US20110086422A1 (en)	2011-04-14
MXPA05011406A (es)	2005-12-12
AU2004233346B2 (en)	2008-03-06
JP2011032292A (ja)	2011-02-17
JP2009298818A (ja)	2009-12-24

Legal Events

Date	Code	Title	Description
2012-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ZA200508389B (en)	2006-10-25	Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2005103081A3 (en)	2005-12-01	Human monoclonal antibodies against cd20
EA200702053A1 (ru)	2008-02-28	Антитела против cd38 для лечения множественной миеломы
CY1112277T1 (el)	2015-12-09	ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE502052T1 (de)	2011-04-15	Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
DK1406656T3 (da)	2013-04-15	Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
EA201100923A1 (ru)	2011-12-30	Антитела человека против тканевого фактора
EA200801509A1 (ru)	2008-12-30	Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
CY1111622T1 (el)	2015-10-07	Ανθρωποποιημενοι ανταγωνιστες anti-cmet
ATE455127T1 (de)	2010-01-15	Humane anti-humane cd3-bindungsmoleküle
WO2007062245A3 (en)	2007-12-06	Human monoclonal antibody human cd134 (ox40) and methods of making and using same
DK1734995T3 (da)	2010-10-25	Monoklonale antistoffer og hepatocyytvækstfaktor
CY1113224T1 (el)	2016-04-13	Νεο αντισωμα αντι-ρlgf
WO2009061996A3 (en)	2009-09-03	Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
TW200722437A (en)	2007-06-16	Anti-TrkB monoclonal antibodies and uses thereof
LT3312197T (lt)	2019-11-11	Monokloniniai antikūnai prieš klaudiną 18, skirti vėžio gydymui
BR0315157A (pt)	2005-08-09	Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
ATE549033T1 (de)	2012-03-15	Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
DE60142614D1 (de)	2010-09-02	Inität
MY143963A (en)	2011-07-29	Therapeutic binding molecules
DK1411962T3 (da)	2011-04-04	Terapi for pancreacancer med monoklonalt stof
WO2008042941A3 (en)	2008-12-11	Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
WO2004087759A3 (en)	2004-12-23	Method and compositions for conversion of antibody activity
EA202190387A1 (ru)	2022-01-31	Антитело к cd38 человека и его применение
CY1116887T1 (el)	2017-04-05	Anti-cd19 αντισωματα και χρησεις στην ογκολογια